Add to ORKGSafety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosu
Background: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating protein, was the...
IntroductionBelimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of ac...
Abstract: In March 2011, the FDA approved belimumab (Benlysta) for the treatment of adult patients w...
Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combi...
Objective. To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combi...
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentat...
Background: Belimumab is the unique biologic therapy available for patients with SLE. Objectives: To...
Objective: To investigate efficacy, safety and survival of belimumab and to identify predictors of d...
Organ damage is a key determinant of poor long-term prognosis and early death in patients with syste...
Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated autoimmune disease whi...
OBJECTIVE: To investigate efficacy, safety and survival of belimumab and to identify predictors of ...
© 2019 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of Ameri...
OBJECTIVE: To investigate effectiveness and safety of belimumab in patients with active systemic l...
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of int...
Background: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating protein, was the...
IntroductionBelimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of ac...
Abstract: In March 2011, the FDA approved belimumab (Benlysta) for the treatment of adult patients w...
Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combi...
Objective. To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combi...
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentat...
Background: Belimumab is the unique biologic therapy available for patients with SLE. Objectives: To...
Objective: To investigate efficacy, safety and survival of belimumab and to identify predictors of d...
Organ damage is a key determinant of poor long-term prognosis and early death in patients with syste...
Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated autoimmune disease whi...
OBJECTIVE: To investigate efficacy, safety and survival of belimumab and to identify predictors of ...
© 2019 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of Ameri...
OBJECTIVE: To investigate effectiveness and safety of belimumab in patients with active systemic l...
Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...
We investigated whether belimumab treatment impacts on levels of autoantibodies and cytokines of int...
Background: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating protein, was the...
IntroductionBelimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of ac...
Abstract: In March 2011, the FDA approved belimumab (Benlysta) for the treatment of adult patients w...